Cargando…

Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2

PURPOSE: Current interpretation guidelines for germline variants in high-risk cancer susceptibility genes consider predicted loss-of-function (LoF) variants, such as nonsense variants and variants in the canonical splice site sequences ofBRCA2, to be associated with high cancer risk. However, some v...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesman, Romy L. S., Calléja, Fabienne M. G. R., de la Hoya, Miguel, Devilee, Peter, van Asperen, Christi J., Vrieling, Harry, Vreeswijk, Maaike P. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394881/
https://www.ncbi.nlm.nih.gov/pubmed/32398771
http://dx.doi.org/10.1038/s41436-020-0814-5
_version_ 1783565297930731520
author Mesman, Romy L. S.
Calléja, Fabienne M. G. R.
de la Hoya, Miguel
Devilee, Peter
van Asperen, Christi J.
Vrieling, Harry
Vreeswijk, Maaike P. G.
author_facet Mesman, Romy L. S.
Calléja, Fabienne M. G. R.
de la Hoya, Miguel
Devilee, Peter
van Asperen, Christi J.
Vrieling, Harry
Vreeswijk, Maaike P. G.
author_sort Mesman, Romy L. S.
collection PubMed
description PURPOSE: Current interpretation guidelines for germline variants in high-risk cancer susceptibility genes consider predicted loss-of-function (LoF) variants, such as nonsense variants and variants in the canonical splice site sequences ofBRCA2, to be associated with high cancer risk. However, some variant alleles produce alternative transcripts that encode (partially) functional protein isoforms leading to possible incorrect risk estimations. For accurate classification of variants it is therefore essential that alternative transcripts are identified and functionally characterized. METHODS: We systematically evaluated a large panel of human BRCA2 variants for the production of alternative transcripts and assessed their capacity to exert BRCA2 protein functionality. Evaluated variants included all single-exon deletions, various multiple-exon deletions, intronic variants at the canonical splice donor and acceptor sequences, and variants that previously have been shown to affect messenger RNA (mRNA) splicing in carriers. RESULTS: Multiple alternative transcripts encoding (partially) functional protein isoforms were identified (e.g., ∆[E4–E7], ∆[E6–E7], ∆E[6q39_E8], ∆[E10], ∆[E12], ∆E[12–14]). Expression of these transcripts did attenuate the impact of predicted LoF variants such as the canonical splice site variants c.631+2T>G, c.517-2A>G, c.6842-2A>G, c.6937+1G>A, and nonsense variants c.491T>A, c.581G>A, and c.6901G>T. CONCLUSION: These results allow refinement of variant interpretation guidelines for BRCA2 by providing insight into the functional consequences of naturally occurring and variant-related alternative splicing events.
format Online
Article
Text
id pubmed-7394881
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-73948812020-08-11 Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2 Mesman, Romy L. S. Calléja, Fabienne M. G. R. de la Hoya, Miguel Devilee, Peter van Asperen, Christi J. Vrieling, Harry Vreeswijk, Maaike P. G. Genet Med Article PURPOSE: Current interpretation guidelines for germline variants in high-risk cancer susceptibility genes consider predicted loss-of-function (LoF) variants, such as nonsense variants and variants in the canonical splice site sequences ofBRCA2, to be associated with high cancer risk. However, some variant alleles produce alternative transcripts that encode (partially) functional protein isoforms leading to possible incorrect risk estimations. For accurate classification of variants it is therefore essential that alternative transcripts are identified and functionally characterized. METHODS: We systematically evaluated a large panel of human BRCA2 variants for the production of alternative transcripts and assessed their capacity to exert BRCA2 protein functionality. Evaluated variants included all single-exon deletions, various multiple-exon deletions, intronic variants at the canonical splice donor and acceptor sequences, and variants that previously have been shown to affect messenger RNA (mRNA) splicing in carriers. RESULTS: Multiple alternative transcripts encoding (partially) functional protein isoforms were identified (e.g., ∆[E4–E7], ∆[E6–E7], ∆E[6q39_E8], ∆[E10], ∆[E12], ∆E[12–14]). Expression of these transcripts did attenuate the impact of predicted LoF variants such as the canonical splice site variants c.631+2T>G, c.517-2A>G, c.6842-2A>G, c.6937+1G>A, and nonsense variants c.491T>A, c.581G>A, and c.6901G>T. CONCLUSION: These results allow refinement of variant interpretation guidelines for BRCA2 by providing insight into the functional consequences of naturally occurring and variant-related alternative splicing events. Nature Publishing Group US 2020-05-13 2020 /pmc/articles/PMC7394881/ /pubmed/32398771 http://dx.doi.org/10.1038/s41436-020-0814-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Article
Mesman, Romy L. S.
Calléja, Fabienne M. G. R.
de la Hoya, Miguel
Devilee, Peter
van Asperen, Christi J.
Vrieling, Harry
Vreeswijk, Maaike P. G.
Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
title Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
title_full Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
title_fullStr Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
title_full_unstemmed Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
title_short Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
title_sort alternative mrna splicing can attenuate the pathogenicity of presumed loss-of-function variants in brca2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394881/
https://www.ncbi.nlm.nih.gov/pubmed/32398771
http://dx.doi.org/10.1038/s41436-020-0814-5
work_keys_str_mv AT mesmanromyls alternativemrnasplicingcanattenuatethepathogenicityofpresumedlossoffunctionvariantsinbrca2
AT callejafabiennemgr alternativemrnasplicingcanattenuatethepathogenicityofpresumedlossoffunctionvariantsinbrca2
AT delahoyamiguel alternativemrnasplicingcanattenuatethepathogenicityofpresumedlossoffunctionvariantsinbrca2
AT devileepeter alternativemrnasplicingcanattenuatethepathogenicityofpresumedlossoffunctionvariantsinbrca2
AT vanasperenchristij alternativemrnasplicingcanattenuatethepathogenicityofpresumedlossoffunctionvariantsinbrca2
AT vrielingharry alternativemrnasplicingcanattenuatethepathogenicityofpresumedlossoffunctionvariantsinbrca2
AT vreeswijkmaaikepg alternativemrnasplicingcanattenuatethepathogenicityofpresumedlossoffunctionvariantsinbrca2